natgillin/translations-raw huggingface dataset:
Physicians should carefully consider whether their patients with certain underlying conditions, such as severe left ventricular outflow obstruction, fluid depletion, autonomic hypotension or patients with resting hypotension, could be adversely affected by such vasodilatory effects.
Zdravnik naj skrbno ovrednoti, ali bi lahko vazodilatacijski učinek negativno vplival na določena že prisotna stanja, kot so huda zapora iztoka iz levega ventrikla, izguba tekočine, autonomna hipotenzija ali prikrita hipotenzija.
NAME OF THE MEDICINAL PRODUCT ADCIRCA 20 mg tablets tadalafil
IME ZDRAVILA ADCIRCA 20 mg tablete tadalafil
The following groups of patients with cardiovascular disease were not included in PAH clinical studies:
Naslednje skupine bolnikov s srčno-žilno boleznijo niso bile vključene v klinične študije PAH: - bolniki s klinično pomembno okvaro aortne in mitralne zaklopke,
Only tadalafil 40 mg achieved the protocol defined level of significance with a placeboadjusted median increase in 6MWD of 26 metres (p=0.0004; 95 % CI: 9.5, 44.0; Pre-specified Hodges-Lehman method) (mean 33 metres, 95 % CI: 15.2, 50.3).
(p=0,0004; 95 % interval zaupanja: 9,5, 44,0; predhodno določena Hodges-Lehmanova metoda) (povprečna vrednost 33 metrov, 95 % interval zaupanja: 15,2, 50,3).
- Patients with clinically significant aortic and mitral valve disease - Patients with pericardial constriction - Patients with restrictive or congestive cardiomyopathy - Patients with significant left ventricular dysfunction - Patients with life-threatening arrhythmias - Patients with symptomatic coronary artery disease - Patients with uncontrolled hypertension.
- bolniki s konstrikcijo perikarda, - bolniki z restriktivno ali kongestivno kardiomiopatijo, - bolniki z znatno poslabšanim delovanjem levega ventrikla,
ADCIRCA 20 mg film-coated tablets Tadalafil
ADCIRCA 20 mg filmsko obložene tablete tadalafil
Method of administration ADCIRCA is for oral use.
Zdravilo ADCIRCA je za peroralno uporabo.
Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied and therefore dosing of tadalafil in these patients is not recommended.
Pri bolnikih s hudo okvarjenim delovanjem jeter (razred C po Child-Pughu) študij niso opravljali, zato se uporaba tadalafila pri teh bolnikih ne priporoča.
Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7 g/kg or approximately 180 ml of 40 % alcohol [vodka] in an 80 kg male), but in some subjects, postural dizziness and orthostatic hypotension were observed.
Tadalafil (20 mg) ni povečal srednjega znižanja krvnega tlaka, ki ga je povzročil alkohol (0,7 g/kg ali približno 180 ml
Tell your doctor or pharmacist if you are already taking: - bosentan (another treatment for pulmonary aterial hypertension) - nitrates (for chest pain) - alpha blockers used to treat high blood pressure or prostate problems.
Povejte zdravniku ali farmacevtu, če že jemljete: - bosentan (drugo zdravljenje pljučne arterijske hipertenzije),
NAME OF THE MEDICINAL PRODUCT ADCIRCA 20 mg film-coated tablets
IME ZDRAVILA ADCIRCA 20 mg filmsko obložene tablete
Palpitations2, 5
Srčne bolezni palpitacije2,5
ADCIRCA is supplied as a 20 mg tablet.
Zdravilo ADCIRCA je na voljo kot 20 mg tableta.
No dose adjustment is warranted.
Prilagoditev odmerka ni potrebna.
Analyses of observational data suggest an increased risk of acute NAION in men with erectile dysfunction following exposure to tadalafil or other PDE5 inhibitors.
NAION pri moških z erektilno disfunkcijo po izpostavljenosti tadalafilu ali drugim zaviralcem PDE5.
The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).
Tadalafil (10 mg) ni okrepil učinka alkohola na kognitivne funkcije.
Healthy elderly subjects (65 years or over), had a lower oral clearance of tadalafil, resulting in 25 % higher exposure (AUC) relative to healthy subjects aged 19 to 45 years after a 10 mg dose.
Zdrave starejše osebe (65 let ali več) so imele nižji peroralni očistek tadalafila, kar je po odmerku 10
If you experience any of the following side effects stop using the medicine and seek medical help immediately: - allergic reactions including skin rashes (frequency common).
Če se pojavijo kateri koli od naslednjih neželenih učinkov, prenehajte jemati zdravilo in takoj poiščite zdravniško pomoč:
Τηλ: +357 22 715000
Phadisco Ltd Τηλ: + 357 22 715000
In patients with mild to moderate renal impairment a starting dose of 20 mg once per day is recommended.
Okvarjeno delovanje ledvic: Pri bolnikih z blago do zmerno okvarjenim delovanjem ledvic je priporočen začetni odmerek 20 mg enkrat na dan. Odmerek se lahko zveča na 40 mg enkrat na dan, odvisno od učinkovitosti in prenašanja zdravila pri posamezniku.
The placebo-adjusted median increase in 6MWD was 17 metres (p=0.09; 95 % CI: : -7.1, 43.0; Prespecified Hodges-Lehman method) (mean 23 metres, 95 % CI; -2.4, 47.8) in those patients who received tadalafil 40 mg in addition to their concomitant bosentan (n=39), and was 39 metres (p<0.01, 95 % CI:13.0, 66.0; Pre-specified Hodges-Lehman method) (mean 44 metres, 95 % CI: 19.7, 69.0) in those patients who received tadalafil 40 mg alone (n=37).
interval zaupanja: -2,4, 47,8) in pri bolnikih, ki so prejemali samo 40 mg tadalafila (n=37), 39 metrov (p<0,01; 95 % interval zaupanja: 13,0, 66,0; predhodno določena Hodges-Lehmanova metoda)
If you get any side effects, talk to your doctor or pharmacist.
- Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali s farmacevtom.
ADCIRCA is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).
funkcijskem razredu po razvrstitvi SZO pri odraslih, za izboljšanje sposobnosti za telesno obremenitev (glejte poglavje 5.1).
These events were not seen in clinical studies for pulmonary arterial hypertension and therefore frequency is unknown: - swelling of the eyelids, eye pain, red eyes, heart attack and stroke.
Teh učinkov v kliničnih študijah za pljučno arterijsko hipertenzijo niso opazili, zato je pogostnost neznana:
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg tadalafil.
Ena filmsko obložena tableta vsebuje 20 mg tadalafila.
Pain in extremity (including limb discomfort)
bolečina v hrbtu, bolečina v udih (vključno z nelagodjem v udih)
Alcohol concentrations were not affected by co-administration with tadalafil (10 mg or 20 mg).
Alkohol Sočasno jemanje tadalafila (10 mg ali 20 mg) ni vplivalo na koncentracije alkohola.
NN:
Kljub temu,
Priapism has been reported in men treated with PDE5 inhibitors.
Priapizem in anatomska deformacija penisa Pri moških, ki so se zdravili z zaviralci PDE5, so poročali o priapizmu.
Pulmonary arterial hypertension (PAH) etiologies were predominantly idiopathic PAH (61.0 %) and related to collagen vascular disease (23.5 %).
(61,0 %) in povezana z vaskularno sistemsko boleznijo veziva (23,5 %).
Uncommon (may affect up to 1in 100 people) - seizures, passing memory loss, hives, excessive sweating, penile bleeding, presence of blood in semen and/or urine, high blood pressure, fast heart rate, sudden cardiac death and ringing in the ears.
prisotnost krvi v spermi in/ali v urinu, zvišan krvni tlak, hitro bitje srca, nenadna srčna smrt in zvonjenje v ušesih.
Dyspepsia (including abdominal pain/discomfort3)
(vključno z bolečino/nelagod jem v trebuhu3)
The following side effects have been very commonly reported in patients taking ADCIRCA (may affect more than 1 in 10 people): headache, flushing, nasal and sinus congestion (blocked nose), nausea, indigestion (including abdominal pain or discomfort), muscle aches, back pain and pain in the extremity (including limb discomfort)
Zelo pogosto so pri bolnikih, ki so jemali zdravilo ADCIRCA, poročali o naslednjih neželenih učinkih (pojavijo se lahko pri več kot 1 od 10 bolnikov): glavobol, zardevanje, nosna in sinusna kongestija
Warnings and precautions Talk to your doctor before taking ADCIRCA.
Pred začetkom jemanja zdravila ADCIRCA se posvetujte s svojim zdravnikom.
Due to limited clinical experience in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B), following single doses of 10 mg, a starting dose of 20 mg once per day may be considered.
Zaradi malo kliničnih izkušenj pri bolnikih z blago do zmerno cirozo jeter (razred A in B po Child
Before taking the tablets, tell your doctor if you have:
Pred jemanjem zdravila se pogovorite s svojim zdravnikom, če imate: - poleg pljučne hipertenzije še kakšno drugo težavo s srcem,
Additionally, improvements compared to placebo were observed with tadalafil 40 mg in the physical functioning, role-physical, bodily pain, general health, vitality and social functioning domains of the SF-36.
36: fizično funkcioniranje, fizična vloga, telesna bolečina, splošno zdravstveno stanje, vitalnost in socialna funkcija.
Vascular disorders Flushing
Žilne bolezni zardevanje hipotenzija hipertenzija
Haematuria Reproductive system and breast disorders Increased uterine bleeding4
Motnje reprodukcije in dojk podaljšano krvavenje iz maternice priapizem5, krvavitev iz penisa, hematospermija podaljšane erekcije
Ketoconazole (200 mg daily), increased tadalafil (10 mg) single dose exposure (AUC) 2-fold and Cmax by 15 %, relative to the AUC and Cmax values for tadalafil alone.
Ketokonazol (200 mg na dan) je biološko uporabnost (AUC) tadalafila (10 mg) po enkratnem odmerku povečal za 2-krat in Cmax za 15 % glede na vrednosti AUC in Cmax za tadalafil sam. Ketokonazol (400 mg na dan) je povečal biološko uporabnost (AUC) tadalafila (20 mg) za 4-krat in Cmax za 22 %.
Bosentan (125 mg twice daily), a substrate of CYP2C9 and CYP3A4 and a moderate inducer of CYP3A4, CYP2C9 and possibly CYP2C19, reduced tadalafil (40 mg once per day) systemic exposure by 42 % and Cmax by 27 % following multiple dose co-administration.
Antagonisti receptorja za endotelin -1 (npr. bosentan) Bosentan (125 mg dvakrat na dan), ki je substrat CYP2C9 in CYP3A4 in zmeren induktor CYP3A4,
Ask your doctor or pharmacist for advice before taking any medicine while pregnant or breastfeeding.
Če ste noseči ali dojite, se po nasvet o uporabi katerega koli zdravila obrnite na zdravnika ali farmacevta.
Hypotension Hypertension Respiratory, thoracic and mediastinal disorders Nasopharyngitis (including nasal congestion, sinus congestion and rhinitis)
(vključno s nosno kongestijo, sinusno kongestijo in rinitisom)
Alcohol
ZDRAVILA
How to store ADCIRCA
Shranjevanje zdravila ADCIRCA
Visual defects and cases of NAION have been reported in connection with the intake of tadalafil and other PDE5 inhibitors.
V povezavi z jemanjem tadalafila in drugih zaviralcev PDE5 so poročali o okvarah vida in primerih
(5) The adverse reactions have been included in the table as a result of postmarketing or clinical study data from the use of tadalafil in the treatment of erectile dysfunction; and in addition, the frequency estimates are based on only 1 or 2 patients experiencing the adverse reaction in the pivotal placebocontrolled study of ADCIRCA.
(5) Neželeni učinki so bili vključeni v preglednico kot posledica podatkov iz obdobja trženja ali podatkov iz kliničnih študij o uporabi tadafila za zdravljenje erektilne disfunkcije.
Prolonged erections
Bolnike z erekcijami, ki trajajo
Phadisco Ltd
Produtos Farmacêuticos, Lda.
Excipient with known effect:
Redko so poročali o neželenih učinkih:
Facial oedema,
Bolezni sečil hematurija
Gastrointestinal disorders Nausea,
Bolniki z znano dedno degenerativno okvaro očesne mrežnice,
Placebo was not effective in any of the patients.
Placebo ni bil učinkovit pri nobenemu bolniku.
The European Commission granted a marketing authorisation valid throughout the European Union for Krystexxa on 8 January 2013.
Evropska komisija je dovoljenje za promet z zdravilom Krystexxa, veljavno po vsej Evropski uniji, odobrila dne 8. januarja 2013.
The full EPAR for Krystexxa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Krystexxa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Although there may be serious side effects (such as infusion reactions and gout flares) these were considered manageable.
Čeprav lahko pride do resnih neželenih učinkov (kot so reakcije na infundiranje in napadi protina), so bili ti ocenjeni kot obvladljivi.
The company that makes Krystexxa will carry out a study of the long-term safety of the medicine, including its safety and effectiveness in patients who stop treatment and later restart it.
Družba, ki proizvaja zdravilo Krystexxa, bo izvedla študijo o dolgoročni varnosti tega zdravila, vključno z varnostjo in učinkovitostjo pri bolnikih, ki prenehajo z zdravljenjem in kasneje ponovno začnejo z njim.
This is a summary of the European public assessment report (EPAR) for Krystexxa.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Krystexxa.
This lowers the levels of uric acid in the blood.
To znižuje ravni sečne kisline v krvi.
Krystexxa pegloticase
Krystexxa peglotikaza
To reduce the risk of these reactions, patients are given other medicines before treatment with Krystexxa.
Da bi zmanjšali tveganje teh reakcij, bolniki pred zdravljenjem z zdravilom Krystexxa prejmejo tudi druga zdravila.
Reactions are more common in patients who develop antibodies (proteins produced by the immune system, the body's natural defences) that reduce the effect of the treatment.
Reakcije so pogostejše pri bolnikih, ki razvijejo protitelesa (beljakovine, ki jih proizvede imunski sistem, naravni obrambni sistem telesa), ki zmanjšajo učinek zdravljenja.
Overall, 42% of patients (36 out of 85) given the medicine every two weeks showed a persistent response; the figure for those given Krystexxa every four weeks was 35% (29 out of 84).
Skupaj je 42 % bolnikov (36 od 85), ki so prejemali zdravilo Krystexxa vsaka dva tedna, izkazalo dolgotrajen odziv na zdravljenje; pri tistih, ki so zdravilo Krystexxa prejemali vsake štiri tedne, je ta delež znašal 35 % (29 od 84).
The effects of Krystexxa were first tested in experimental models before being studied in humans.
Učinki zdravila Krystexxa so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
For more information about treatment with Krystexxa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Krystexxa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Although uric acid levels were quickly lowered by Krystexxa, its effect was reduced within a few weeks in more than half the patients.
Čeprav je zdravilo Krystexxa hitro znižalo ravni sečne kisline, se je ta učinek v nekaj tednih zmanjšal pri več kot polovici bolnikov.
What measures are being taken to ensure the safe use of Krystexxa?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Krystexxa?
The main measure of effectiveness was the number of patients who showed a persistent response to the treatment, defined as uric acid level in the blood below 6 mg/dl for at least 80% of the time during both the third and sixth months of the study.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so izkazali dolgotrajen odziv na zdravljenje, opredeljen kot znižanje ravni sečne kisline v krvi pod 6 mg/dl v vsaj 80 % časa med tretjim in med šestim mesecem študije.
The CHMP therefore decided that Krystexxa's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zato zaključil, da so koristi zdravila Krystexxa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The most common serious side effects with Krystexxa are anaphylaxis (a severe allergic reaction), seen in about 7 patients in 100, infusion reactions (including flushing, skin rashes, itching, sweating, chest pain, difficulty in breathing, chills, and raised blood pressure), seen in about 26 patients in 100, and gout flares (worsening of gout symptoms) which were more common in the first 3 months of treatment.
Najpogostejši resni neželeni učinki zdravila Krystexxa so anafilaksija (huda alergijska reakcija), opažena pri približno 7 bolnikih od 100, reakcije na infundiranje (vključno z zardevanjem, kožnimi izpuščaji, srbenjem, potenjem, bolečinami v prsnem košu, težavami z dihanjem, mrzlico in povišanim krvnim tlakom), opažene pri približno 26 bolnikih od 100 in napadi protina (poslabšanje simptomov protina), ki so bili pogostejši v prvih treh mesecih zdravljenja.
All patients are monitored for any reactions during the infusion and for at least one hour afterwards.
Pri vseh bolnikih je treba preverjati, ali med infundiranjem in še najmanj eno uro po njem morebiti ni prišlo do pojava kakršnih koli reakcij.
Other information about Krystexxa
Druge informacije o zdravilu Krystexxa
Krystexxa, given at a dose of 8 mg every two or four weeks, was compared with placebo (a dummy treatment), over a period of six months.
Zdravilo Krystexxa, dano v odmerku 8 mg vsake dva ali štiri tedne, so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju šestih mesecev.
Krystexxa is used to treat adult patients with severe chronic (long-term) tophaceous gout.
Zdravilo Krystexxa se uporablja za zdravljenje odraslih bolnikov s hudim kroničnim (dolgotrajnim) protinom s tofi.
Krystexxa must not be used in people who are hypersensitive (allergic) to pegloticase or any of the other ingredients, and in people with a rare blood disorder called glucose 6-phosphate dehydrogenase (G6PD) deficiency (favism) or similar disorders.
Zdravila Krystexxa ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) peglotikazo ali katero koli drugo sestavino zdravila, in osebe z redko krvno motnjo, imenovano pomanjkanje glukoza6-fosfat dehidrogenaze (G6PD) (favizem), ali podobnimi motnjami.
This is where high levels of the substance uric acid develop in the blood and then crystallise in joints and tissues, forming tophi (stones) that cause pain and joint damage.
To je bolezen, pri kateri se v krvi razvijejo visoke ravni sečne kisline, ki nato kristalizira v sklepih in tkivih ter oblikujejo tofe (kamne), ki povzročajo bolečino v sklepih in njihovo poškodbo.
The uricase in Krystexxa is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce uricase.
Urikaza v zdravilu Krystexxa se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvoriti urikazo.
What benefit has Krystexxa shown during the studies?
Kakšne koristi je zdravilo Krystexxa izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Krystexxa.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Krystexxa, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Treatment with Krystexxa should be given under the supervision of a doctor who has experience in the treatment of severe chronic gout, in a setting where facilities for resuscitation are available.
Zdravljenje z zdravilom Krystexxa je treba izvajati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hudega kroničnega protina, in v okolju, kjer je na voljo oprema za oživljanje.
Uricase breaks down uric acid into another substance, allantoin, which can be passed out of the body in the urine.
Urikaza sečno kislino razgradi v drugo snov, imenovano alantoin, ki se lahko iz telesa izloči z urinom.
Krystexxa was studied in two main studies involving 225 patients with severe tophaceous gout in whom allopurinol, a xanthine oxidase inhibitor, had previously failed to control their uric acid levels or could not be used due to side effects.
Zdravilo Krystexxa so proučili v dveh glavnih študijah, ki sta vključevali 225 bolnikov s hudim protinom s tofi, pri katerih alopurinol, zaviralec ksantin-oksidaze, ni bil uspešen pri nadzorovanju njihovih ravni sečne kisline ali ga ni bilo mogoče uporabljati zaradi neželenih učinkov.
The CHMP concluded that Krystexxa was highly effective in reducing uric acid levels.
CHMP je zaključil, da je bilo zdravilo Krystexxa zelo učinkovito pri zniževanju ravni sečne kisline.
Once levels of uric acid are below 6 mg/dl, this allows crystals in the joints to dissolve, slowly shrinking the tophi.
Ko ravni sečne kisline upadejo pod 6 mg/dl, kristali v sklepih razpadejo, tofi pa se počasi zmanjšajo.
In Krystexxa, uricase has been attached to a chemical, polyethylene glycol (PEG), which decreases the rate at which uricase is removed from the body, allowing its action to last longer.
Pri zdravilu Krystexxa je urikaza vezana na kemikalijo polietilenglikol (PEG), kar zmanjšuje hitrost, s katero se urikaza izloča iz telesa, in tako podaljšuje njeno delovanje.
The active substance in Krystexxa, pegloticase, contains an enzyme called uricase.
Zdravilna učinkovina zdravila Krystexxa, peglotikaza, vsebuje encim, imenovan urikaza.
Krystexxa is a medicine containing the active substance pegloticase.
Krystexxa je zdravilo, ki vsebuje zdravilno učinkovino peglotikaza.
Krystexxa given every two weeks resulted in fewer reactions to the infusion than when it was given every four weeks.
Zdravilo Krystexxa je povzročilo manj reakcij, če je bilo dano vsaka dva tedna, kot če je bilo dano vsake štiri tedne.
What is the risk associated with Krystexxa?
Kakšna tveganja so povezana z zdravilom Krystexxa?
For severely affected patients who cannot be treated effectively with conventional methods, the Committee considered that Krystexxa addressed an unmet need, since no alternative treatments are available.
Odbor je ocenil, da pri huje prizadetih bolnikih, pri katerih učinkovito zdravljenje z običajnimi metodami ni možno, zdravilo Krystexxa edino zadovoljuje njihove potrebe, saj alternativna zdravljenja niso na voljo.
Krystexxa was shown to be more effective than placebo in reducing uric acid levels.
Zdravilo Krystexxa se je pri zniževanju ravni sečne kisline izkazalo za učinkovitejše od placeba.
Why has Krystexxa been approved?
Zakaj je bilo zdravilo Krystexxa odobreno?
Krystexxa is only used in patients who cannot control their uric acid levels even at maximum doses of conventional medicines called xanthine oxidase inhibitors, or who are unable to use such medicines.
Zdravilo Krystexxa se uporablja le pri bolnikih, ki tudi pri jemanju največjih odmerkov običajnih zdravil, imenovanih zaviralci ksantin-oksidaze, ne morejo uravnavati ravni sečne kisline oziroma ki teh zdravil ne morejo jemati.
Krystexxa is given as an infusion into a vein every two weeks, at a recommended dose of 8 mg.
Zdravilo Krystexxa se daje z infundiranjem v veno vsaka dva tedna v priporočenem odmerku 8 mg. Infuzija se daje počasi v trajanju najmanj dveh ur.
For the full list of side effects reported with Krystexxa, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Krystexxa, glejte navodilo za uporabo.
For further information on the use of Krystexxa see the package leaflet.
Za podrobnejše informacije o uporabi zdravila Krystexxa glejte navodilo za uporabo.
What is Krystexxa used for?
Za kaj se zdravilo Krystexxa uporablja?
How does Krystexxa work?
Kako zdravilo Krystexxa deluje?
How has Krystexxa been studied?
Kako je bilo zdravilo Krystexxa raziskano?
How is Krystexxa used?
Kako se zdravilo Krystexxa uporablja?
What is Krystexxa?
Kaj je zdravilo Krystexxa?